EBM Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


First published online June 5, 2008
Experimental Biology and Medicine doi: 10.3181/0802-MR-47
© 2008 by the Society for Experimental Biology and Medicine

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
233/9/1059    most recent
0802-MR-47v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Kang, Y. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kang, Y. J.


Mini Review

Herbogenomics: From Traditional Chinese Medicine to Novel Therapeutics

Y. James Kang 1*

1 University of Louisville

* To whom correspondence should be addressed. E-mail: yjkang01{at}louisville.edu.


   Abstract

Traditional Chinese medicine (TCM) has a long history of development and application and has been demonstrated on evidence basis its efficacy in the treatment of many diseases affecting multiple organ systems. In particular, TCM is effective in the prevention and treatment of chronic diseases and metabolic syndromes. However, the value of TCM has not been fully recognized worldwide due to the lack of definitive information of active ingredients in almost any TCM preparation. Novel functional genomics and proteomics approaches provide alternate perspectives on the mechanism of action of TCM. The target molecules on which TCM either activates or inactivates can be identified by functional genomics and proteomics, thus the affected critical signaling pathway cascades leading to effective recovery of chronic diseases can be studied. Several TCM preparations have been available for the treatment of liver fibrosis and cirrhosis, even advanced liver cirrhosis that has been shown to be irreversible and have no US-FDA approved therapy. In the TCM-treated livers with fibrosis and cirrhosis, some critical molecules that are significantly involved in the recovery can be identified through functional genomics and proteomics studies. These molecules become novel targets for drug discovery and development and candidates for the development of gene therapy. Gene therapy developed based on this strategy for the treatment of advanced liver fibrosis and cirrhosis in animal models has obtained promising results. This process thus establishes a herbogenomics approach to understand mechanisms of action of TCM and to identify effective molecular targets for the discovery and development of novel therapeutics.

Key Words: TCM, Gene Therapy, personal medicine, liver fibrosis, proteomics, genomics







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by the Society for Experimental Biology and Medicine.